Publications

Huang SS, Chen CL, Huang FW, Hou WH, Huang JS. DMSO Enhances TGF-β Activity by Recruiting the Type II TGF-β Receptor From Intracellular Vesicles to the Plasma Membrane. Journal of cellular biochemistry. 2016. PMID: 26587792


DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia & lymphoma. 2016. PMID: 26892479


Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016. PMID: 26899561


Borno H, Siegel A, Ryan C. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. Journal of health services research & policy. 2016. PMID: 26888478


Pichler J, Ong C, Shah N, Sebire N, Kiparrissi F, Borrelli O, Pilkington C, Elawad M. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatric research. 2016. PMID: 26882369


Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PloS one. 2016. PMID: 26881434


H Jiang, N Denduluri, M Majure, A Favret, HS Rugo. Abstract P5-08-06: Comparison of risk prediction with the 21-gene recurrence score (oncotype DX) and the 70-gene signature (MammaPrint) in patients with estrogen receptor-positive early stage breast cancer. Poster Session Abstracts. 2016. PMID:


Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast cancer research and treatment. 2016. PMID: 26875185


Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer research. 2016. PMID: 26873845


Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast cancer research and treatment. 2016. PMID: 26868124


Barber JL, Lozinsky AC, Kiparissi F, Shah N, Watson TA. Detecting inflammation in the unprepared pediatric colon - how reliable is magnetic resonance enterography? Pediatric radiology. 2016. PMID: 26867608


Rugo HS, Chien AJ. HER2-positive breast cancer: is more treatment better? The Lancet. Oncology. 2016. PMID: 26874902


Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin. Breast cancer research and treatment. 2016. PMID: 26860947


Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016. PMID: 26834058


Mulvey CK, Bergsland EK. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematology/oncology clinics of North America. 2016. PMID: 26614369


Tempero M. Put Us Out of Business--Please! Journal of the National Comprehensive Cancer Network : JNCCN. 2016. PMID: 26850482


Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016. PMID: 26811525


Wei XX, Fong L, Small EJ. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert opinion on biological therapy. 2016. PMID: 26698365


McElroy LM, Woods DM, Yanes AF, Skaro AI, Daud A, Curtis T, Wymore E, Holl JL, Abecassis MM, Ladner DP. Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical population. International journal for quality in health care : journal of the International Society for Quality in Health Care. 2016. PMID: 26803539


Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Volume 27 of Issue 4 Annals of oncology : official journal of the European Society for Medical Oncology. 2016. PMID: 26802160